B
Barbara Da Silva-Tillmann
Researcher at AbbVie
Publications - 6
Citations - 1200
Barbara Da Silva-Tillmann is an academic researcher from AbbVie. The author has contributed to research in topics: Ombitasvir & Dasabuvir. The author has an hindex of 5, co-authored 6 publications receiving 1151 citations.
Papers
More filters
Journal ArticleDOI
ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
Fred Poordad,Christophe Hézode,Roger Trinh,Kris V. Kowdley,Stefan Zeuzem,Kosh Agarwal,Mitchell L. Shiffman,Heiner Wedemeyer,Thomas Berg,Eric M. Yoshida,Xavier Forns,Sandra S. Lovell,Barbara Da Silva-Tillmann,Christine Collins,Campbell Andrew L,Thomas Podsadecki,B. Bernstein +16 more
TL;DR: In this phase 3 trial of an oral, interferon-free regimen evaluated exclusively in patients with HCV genotype 1 infection and cirrhosis, multitargeted therapy with the use of three new antiviral agents and ribavirin resulted in high rates of sustained virology response.
Journal ArticleDOI
Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1: A Randomized Trial
Mark S. Sulkowski,Joseph J. Eron,David L. Wyles,Roger Trinh,J. Lalezari,Chia Wang,Jihad Slim,Laveeza Bhatti,Joseph Gathe,Peter Ruane,Richard Elion,Fritz Bredeek,Robert Brennan,Gary Blick,Amit Khatri,Krystal Gibbons,Yiran B Hu,Linda M Fredrick,Gretja Schnell,Tami Pilot-Matias,Rakesh Tripathi,Barbara Da Silva-Tillmann,Barbara H. McGovern,Campbell Andrew L,Thomas Podsadecki +24 more
TL;DR: Treatment with the all-oral, interferon-free 3D-plus-ribavirin regimen resulted in high SVR rates among patients co-infected with HCV genotype 1 and HIV-1 whether treated for 12 or 24 weeks.
Journal ArticleDOI
Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program
Philip G. Conaghan,Eduardo Mysler,Yoshiya Tanaka,Barbara Da Silva-Tillmann,T. Shaw,J. Liu,Ryan Ferguson,Jeffrey Enejosa,Stanley N. Cohen,Peter Nash,William F. C. Rigby,Gerd R Burmester +11 more
TL;DR: In this article, upadacitinib 15 mg was associated with increased risk of herpes zoster and creatine phosphokinase elevations compared with placebo, methotrexate and adalimumab but otherwise had comparable safety with these active comparators.
Journal ArticleDOI
Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens.
Joseph J. Eron,J. Lalezari,Jihad Slim,Joseph Gathe,Peter Ruane,Chia Wang,Richard Elion,Gary Blick,Amit Khatri,Yiran B Hu,Krystal Gibbons,Linda M Fredrick,Melannie Co,Ronald D'Amico,Barbara Da Silva-Tillmann,Roger Trinh,Mark S. Sulkowski +16 more
TL;DR: 3 direct‐acting antiviral regimen of ombitasvir, ABT‐450 and dasabuvir is assessed in HCV/HIV‐1 co‐infected patients with and without cirrhosis, including HCV treatment‐experienced, receiving atazanavir (ATV)‐ or raltegravir (RAL)‐based ART therapy.
Journal Article
Safety of ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients >= 65 Years of Age: Results From Phase 2 and 3 Trials
Steven L. Flamm,Edward Gane,Jean-Francois J. DuFour,Vinod K. Rustgi,Vincent G. Bain,Darrell H. G. Crawford,Pietro Andreone,Tarek Hassanein,Włodzimierz Mazur,Sandra S. Lovell,Barbara Da Silva-Tillmann,Nancy S. Shulman,Massimo Puoti,Terry Box,Ira M. Jacobson +14 more